post stroke clinical trials results

anticoagulant versus no anticoagulant
Baker, 1964
unnamed anticoagulant (TQ (2 to 2.5 times control in seconds), started in hospital
versus
no treatment
open
Bradshaw, 1975
warfarin or phenindione for 18 mo; TP time 2x control
versus
no treatment
open
UK
LHSPS, 1999
unfractionated heparin 12.500 IU/d plus ’usual therapy’
versus
usual therapy
open
Follow-up duration: 2 years
Italy
VA Study, 1961
coumadin or dicumarol, prothrombin activity 20% of normal
versus
no treatment
open
Follow-up duration: 11 months
USA
Wallace, 1964
phenindione or warfarin, Quick test 20% to 35% of normal (50% after 10 months)
versus
no treatment
open
Follow-up duration: 9.75 months
Australia
anticoagulant versus placebo
McDevitt, 1959
dicumarol or warfarin, Quisk test 2 to 2.5 times control in seconds
versus
placebo
single-blind
Follow-up duration: 34 months
USA
aspirin versus placebo
Canadian study (CCSG), 1978
aspirin 325 mg/d
versus
placebo
Double blind
Follow-up duration: ND
Swedish study , 1987
aspirin 1,500 mg/d
versus
placebo

Follow-up duration: 2 y
UK-TIA low dose , 1988
aspirin 300 mg/d
versus
placebo

Follow-up duration: 4 y
UK-TIA high dose , 1988
aspirin 1,200 mg/d
versus
placebo

Follow-up duration: 2y
SALT , 1991
aspirin 75 mg/d
versus
placebo

Follow-up duration: 32 mo
Reuther , 1976
aspirin 1,500 mg/d
versus
placebo

Follow-up duration: 2 y
AITA, 1975
aspirin 1,300 mg/d
versus
placebo

Follow-up duration: 1 y
DCS, 1980
aspirin 1,000 mg/d
versus
placebo

Follow-up duration: 25 mo
AICLA, 1981
aspirin 990 mg/d
versus
placebo

Follow-up duration: 3 y
Lindblad , 1991
aspirin 75 mg/d, during 6 months
versus
placebo

Follow-up duration: 6 mo
Danish low-dose, 1986
aspirin 50-100 mg/d (mean 54 mg/d)
versus
placebo

Follow-up duration: 23 mo
ESPS 2 , 1996
aspirin 50 mg/d
versus
placebo

Follow-up duration: 2 y
atorvastatin versus placebo
SPARCL, 2006
NCT00147602
atorvastatin 80mg daily
versus
placebo
patients who had had a stroke or TIA within one to six months before study entry, had low-density lipoprotein (LDL) cholesterol levels of 2.6 to 4.9 mmol per liter, and had no known coronary heart diseasedouble blind
Follow-up duration: 4.9y (median)
dicoumarol versus placebo
Howard, 1963
dicumarol, TP 15 to 25% of normal
versus
placebo
single-blind
Follow-up duration: 1 year
USA
Nat-Coop, 1962
heparin 50 mg 4-hourly iv then dicumarol, Quick test 15% to 25% of control
versus
placebo
single-blind
Follow-up duration: 13 months
USA
folic acid, vit B12 and vit B6 versus placebo
VITATOPS, 2010
NCT00097669ÐX&
folic acid and vitamins B12 and B6 in a single tablet
versus
placebo
patients with recent stroke or TIA (within the past seven months)double-blind
Follow-up duration: 3.4 y
20 countries
high dose - folic acid, vit B12 and vit B6 versus low dose - folic acid, vit B12 and vit B6
VISP (Toole), 2004
high-dose of folic acid, pyridoxine (vitamin B6), and cobalamin (vitamin B12)
versus
low-dose of folic acid, pyridoxine (vitamin B6), and cobalamin (vitamin B12)
adults with nondisabling cerebral infarctiondouble blind
Follow-up duration: 2 y
United States, Canada, Scotland
phenindione versus placebo
Enger, 1965
phenindione thrombotest 10% to 25% of normal, started in hospital
versus
placebo
single-blind
Follow-up duration: 22.7 months
Norway
Thygesen, 1964
phenindione, prothrombin-proconvertin test 10% to 20%
versus
placebo
single-blind
Follow-up duration: 29.5 months
Denmark
simvastatin versus placebo
HPS (sub groups), 2004
simvastatin 40mg daily
versus
placebo
adults with cerebrovascular disease, total cholesterol >=3·5 mmol/L and without coronaro disease (n=1820)double blind
Starflex versus medical treatment
CLOSURE I, 2010
NCT00201461
patent foramen ovale closure using the Starflex device
versus
best medical therapy: aspirin (325 mg daily) and/or warfarin (target INR = 2.5)
patients with a stroke and/or transient ischemic attack due to presumed paradoxical embolism through a patent foramen ovaleopen
Follow-up duration: 2 years
US, Canada
telmisartan versus placebo
PROFESS, 2008
telmisartan 80 mg/d
versus
placebo
warfarin versus aspirin
SWAT, 1998
warfarin (INR 2.0 to 3.0)
versus
Enteric-coated aspirin 650 mg 12-hourly
open
Follow-up duration: 2 years
USA